{
  "id": 17787941,
  "title": "Regen BioPharma signs $125,000 note and $10 million equity line with Coventry",
  "url": "https://urgent.news/2026/11/02/regen-biopharma-signs-125-000-note-and-10-million-equity-line-with",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T11:30:14.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/sec-filings/regen-biopharma-signs-125000-note-and-10-million-equity-line-with-coventry-93CH-4990877"
  },
  "original_language": "en",
  "account": null,
  "summary": "Regen BioPharma, Inc. (OTC:RGBP) has secured two financing agreements with Coventry Enterprises, LLC. The first agreement involves a $125,000 unsecured promissory note with a 10% annual interest rate over an eighteen-month term, totaling $12,500 in interest. The note is repayable in eight equal monthly installments beginning six months after funds are received. The second agreement is a common stock purchase agreement, in which Coventry has committed to purchase up to $10 million of Regen BioPharma's common stock over a 36-month period. The stock purchase agreement is subject to certain conditions, including the effectiveness of a registration statement covering the resale of shares.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}